Evidence map›Paper›PMID 36204653›Full record

ArticleAmerican journal of preventive cardiology2022

The burden of severe hypercholesterolemia and familial hypercholesterolemia in a population-based setting in the US.

Seyedmohammad Saadatagah, Lubna Alhalabi, Medhat Farwati, Magdi Zordok, Ashwini Bhat, Carin Y Smith, Christina M Wood-Wentz, Kent R Bailey, Iftikhar J Kullo

Open access · goldAbstract read
In one paragraph

Article in American journal of preventive cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Seyedmohammad SaadatagahDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Lubna AlhalabiDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Medhat FarwatiDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Magdi ZordokDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Ashwini BhatDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Carin Y SmithDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA.
Christina M Wood-WentzDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA.
Kent R BaileyDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA.
Iftikhar J KulloDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Arizona · USMayo Clinic · US

Funding

EHR-Based Strategies to Improve Outcomes in Familial HypercholesterolemiaR01HL135879 · NHLBI · MAYO CLINIC ROCHESTER · PI KULLO, IFTIKHAR J · 2017 to 2020
$2.5M
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR33AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2020 to 2022
$2.4M
Patient-Oriented Research in Genomic Discovery and ImplementationK24HL137010 · NHLBI · MAYO CLINIC ROCHESTER · PI KULLO, IFTIKHAR J · 2017 to 2021
$590k
NHLBI NIH HHS K24 HL137010NHLBI NIH HHS R01 HL135879NIA NIH HHS R33 AG058738
6 · The paper itself

Abstract

Background: Contemporary prevalence, awareness, and control of severe hypercholesterolemia (SH) and familial hypercholesterolemia (FH) and the associated atherosclerotic cardiovascular disease risk in the US are unknown. Method: Using electronic health records, we assessed the burden of SH and FH in Olmsted County, Minnesota, US, between 2004 and 2015. We defined SH as low-density lipoprotein cholesterol (LDL-C) level ≥190 mg/dl without secondary causes of hypercholesterolemia and FH as a Dutch Lipid Clinic Network score ≥6. Controls were age- and sex-matched individuals with LDL-C level <190 mg/dl. Results: The age- and sex-adjusted point and period prevalence (age-recursive method) of SH was 4.44% and 8.95%, respectively; 1 in 21 had FH (∼1:233 adults), and 46.2% had a recorded diagnosis. Guideline recommended targets (LDL-C <100 mg/dl and <70 mg/dl in the primary and secondary prevention settings, respectively) were achieved in 33.1% and 21.2% of SH cases, with less women overall achieving the target than men (18.6% vs. 23.7%, p=0.022). After adjustment for conventional risk factors, the hazard ratio for incident coronary heart disease (CHD) in those with SH was 1.21 (1.05-1.39; p=0.010), in those with SH and a family history of CHD was 2.16 (1.57-2.96; p<0.001) and in those with FH was 4.61 (2.66-7.97; p<0.001). The association of SH with CHD was modified by age (p-interaction = 0.015), such that the risk was greater at younger ages. Conclusions: SH was prevalent and an independent risk factor for incident CHD. Awareness and control were low, highlighting a treatment gap (more prominent in women) that needs to be addressed.

Indexed as

ASCVD, atherosclerotic cardiovascular diseaseAtherosclerotic cardiovascular diseaseCHD, coronary heart diseaseCVD, cerebrovascular diseaseDLCN, dutch lipid clinic networkEpidemiologyFamilial hypercholesterolemiaFH, familial hypercholesterolemiaLDL-C, low-density lipoprotein cholesterolLLT, lipid lowering therapyPAD, peripheral artery diseaseSevere hypercholesterolemiaSH, severe hypercholesterolemiaStatin

Identifiers

PMID36204653
PMCPMC9530843
OpenAlexW4297200144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.